InnoBM has recently unveiled the Phase I clinical study data for its TLR7/8 agonist, BM201, which was selected for a preferred oral presentation at the recently concluded ESMO Asia 2024 conference. The scientific meeting of ESMO Asia 2024 took place in Singapore from December 6-8, 2024. During the conference, Dr. Li Rutian, Director of Affiliated Hospital of Medical School, Nanjing University, presented the study data orally as the lead investigator.

Dr. Li Rutian's presentation highlighted the innovative potential of BM201 in addressing a significant unmet medical need for patients with soft tissue sarcomas. InnoBM is committed to advancing its research and development efforts to bring BM201 to market as a transformative treatment option for these patients.

About BM201:
BM201 is a novel long-acting TLR7/8 agonist that continuously activates antigen-presenting cells, enhancing radiotherapy-induced tumor-specific immune responses. It sensitizes tumors to radiotherapy, increases the likelihood of abscopal effects, and has the potential to achieve systemic tumor suppression when combined with PD-1 inhibitors. By triggering sustained immune activation, BM201 aims to provide a transformative therapeutic option for cancer patients.